Alisha Alaimo, Biogen US president (Biogen via YouTube)
January 12, 2022 09:22 AM ESTUpdated 01:56 PM
R&D
Pharma

Ex­clu­sive: Bio­gen pres­i­dent fears CMS will fi­nal­ize re­stric­tive cov­er­age de­ci­sion for Aduhelm, preps plans to flood NCD with com­ments

Zachary Brennan

Senior Editor

While lament­ing yes­ter­day’s pro­posed na­tion­al cov­er­age de­ci­sion for its con­tro­ver­sial Alzheimer’s drug, Bio­gen’s US pres­i­dent Al­isha Alaimo pledged to flood CMS with com­ments over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times